Next-generation probiotics (NGPs), consisting of non-traditional commensal microorganisms with targeted health benefits, are at the forefront of microbiome-based therapeutics. Unlike conventional probiotics, NGPs such as Faecalibacterium prausnitzii, Bacteroides xylanisolvens, Al [....]
» Read More
Effects of a balanced multi-strain synbiotic in patients with moderate to severe irritable bowel syndrome (IBS) of all stool form types were characterized in a multi-center, randomized, double blind, placebo-controlled clinical study. A total of 202 adult IBS patients were random [....]
» Read More
Title : Overcoming manufacturing challenges in next-generation probiotics: From anaerobic cultivation to clinical-grade formulation
Jason Ryan, Sacco System, Australia
Next-generation probiotics (NGPs), consisting of non-traditional commensal microorganisms with targeted health benefits, are at the forefront of microbiome-based therapeutics. Unlike conventional probiotics, NGPs such as Faecalibacterium prausnitzii, Bacteroides xylanisolvens, Al [....] » Read More
Title : Treating irritable bowel syndrome patients with a balanced multi-strain synbiotic – results from a multi-center, randomized, double-blind, placebo-controlled clinical trial (the ViIBS trial)
Henning Sommermeyer, Calisia University, Poland
Effects of a balanced multi-strain synbiotic in patients with moderate to severe irritable bowel syndrome (IBS) of all stool form types were characterized in a multi-center, randomized, double blind, placebo-controlled clinical study. A total of 202 adult IBS patients were random [....] » Read More